Controlled method of reducing electrophoretic mobility of macromolecules, particles, or cells by Vanalstine, James M.
United States Patent 
US005108568A 
[ i i ]  Patent Number: 5,108,568 
Van Alstine [45] Date of Patent: Apr. 28, 1992 
CONTROLLED METHOD OF REDUCING 
ELECFROPHORETIC MOBILITY OF 
MACROMOLECULES, PARTICLES OR 
CELLS 
Inventor: 
Assignee: 
James M. Van Alstine, Huntsville, 
Ala. 
The United States of America as 
represented by the Administrator of 
the National Aeronautics and Space 
Administration, Washington, D.C. 
Appl. No.: 599,601 
Filed: Oct. 18, 1990 
Related U.S. Application Data 
Continuation-in-part of Ser. No. 376,487, Jul. 7, 1989. 
Int. Cl.5 ............................................. GOlN 27/26 
U.S. C1. .............................. 204/180.1; 204/1 83.3; 
204/299 R 
Field of Search .............. 204/180.1, 183.3, 299 R 
References Cited 
U.S. PATENT DOCUMENTS 
3,984,533 10/1976 Uzgiris ........................ 204/299 R X 
4,Ol 1,044 3/1977 Uzgiris ......................... 204/183.3 X 
4,102,990 8/1978 Uzgiris ........................ 204/299 R X 
4,181,589 ]/I980 Brooks ............................. 204/180.1 
4,783,419 11/1988 Hayashi et al. .............. 204/183.3 X 
OTHER PUBLICATIONS 
Muller, W. et al., "Polyethylene Glycol Derivatives of 
Base and Sequence Specific DNA Ligands: DNA Inter- 
action and Application for Base Specific Separation of 
DNA Fragments by Gel Electrophoresis", Nucleic 
Acids Research, vol. 9, No. 1,  (1981), pp. 95-119. 
Primary Examiner-John Niebling 
Assistant Examiner-John S. Starsiak, Jr. 
Attorney, Agent, or Firm-Robert L. Broad, Jr.; Jerry L. 
Seemann; John R. Manning 
P I  ABSTRACI' 
A method of reducing electrophoretic mobility of mac- 
romolecules, particles, cells and other substances is 
provided which comprises interacting in a conventional 
electrophoretic separating procedure the substances 
with a polymer-linked affinity compound comprised of 
a hydrophilic neutral polymer such as polyethylene 
glycol bound to a second component such as a hydro- 
phobic compound, an immunocompound such as an 
antibody or antibody active fragment, or a ligand such 
as a hormone, drug, antigen or a hapten. The reduction 
of electrophoretic mobility achieved is directly propor- 
tional to the concentration of the polymer-linked affn- 
ity compound employed, and such reduction can com- 
prise up to 100% for particular particles and cells. The 
present invention is advantageous in that electropho- 
retic separation can now be achieved for substances 
whose native surface charge structure had prevented 
them from being separated by normal electrophoretic 
means. Depending on the affinity component utilized, 
separation can be achieved on the basis of specifidir- 
reversible, specificheversible, semi-specificheversible, 
relatively nonspecificheversible, or relatively non- 
specific/irreversible ligand-substance interactions. 
10 Claims, 2 Drawing Sheets 
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cells could be separated was theorized as early as the 
CONTROLLED METHOD OF REDUCING 1920's. However. antibody-induced cell aggregation, 
ELECXROPHORETIC MOBILITY OF and a demonstrated lack of cell-antibody interaction 
MACROMOLECULES, PARTICLES OR CELLS appreciably altering substance electrophoretic mobility 
5 has kept this goal at arms length. Previous research in 
ORIGIN O F  THE INVENTION this field attempted to use immuno-compounds and 
The invention described herein was made in the per- other agents to affect electrophoretic mobility Of vari- 
formance of work under a NASA contract and is sub- O w  Cells. For example, Seaman, pgs. 1135-1229 in The 
ject to the provisions of Section 305 of the National Red Blood cell, vel. 3 (19751, discloses modifying red 
Aeronautics and Space Act of 1958, Public Law 85-568 lo blood cell (erythrocyte) surfaces with such materials as 
(72 Stat. 435; 43 U.S.C. 2457). antisera, enzymes, and neutral polymers. In the first two 
This application is a continuation-in-part of U.S. pa- cases (antisera and enzymes), problems were reported 
tent application Ser. No. 07/376,487, filed Jul. 7, 1989. including aggregation, limited reduction of cell mobil- 
ity, and a general lack of specificity in the treatments. It 
l5 was found that the use of freely absorbed neutral poly- FIELD O F  THE INVENTION 
The invention relates in general to a method for quan- mers actually increased particle electrophoretic mobil- 
titatively reducing electrophoretic mobility of macro- ity. Effects of unmodified antibodies on red blood cells 
molecules, particles and cells or other substances, and in (such as indicated above) has also been reported by 
Particular to a method of reducing electrophoretic mo- Sachtleben, in Cell Electrophoresis, pgs. 100-1 14 (1965). 
bility in a concentration-dependent manner by interact- *O The use of a double antibody system yielding up to 
ing these substances with a polymer-linked affinity com- about a 40% reduction in electrophoretic mobility in 
Pound comprising a hydrophilic neutral Polymer bound epithelial cells and lymphocytes was reported in Cohly 
to a second component et a1 in Cell Electrophoresis, pgs. 611-616 (1985). In an 
pound, an immunocompound, or a ligand. attempt to alter net cell surface charge, rather than cell *' surface electrohydrodynamics, these authors exposed 
cells covered with antibodies to secondary anti-antibo- 
and isolate macromolecules and particles due to differ- would partially neutralize the cells native net negative 
have the same charge but different mobilities, the faster 30 These previous attempts in reducing mobility generally 
moving substances will overrun and migrate ahead of suffered from various problems such as aggregation, the slower one. This is usually due to substance geome- and large, controlled reductions in electrophoretic mo- try and other hydrodynamic considerations, e.g., mac- 
romolecular group conformation/surface topography, bility have not been achieved' 
etc. In general, the affinity of one substance for another 35 In the patent many attempts at separating biologi- 
as a hydrophobic 
BACKGROUND O F  THE INVENTION 
For years, has been to separate 
apparent surface charge' When two substances 
dies possessing a net positive charge which they hoped 
enceS charge (due primarily to surface carboxylate groups). 
will affect the mobility of that substance when both are 
subjected to electrophoresis. It is thus theoretically 
possible to maximize separation of particles with the 
Same or similar charge through the use of specific affin- 
cal and Other through electrophoresis 
are known. For instance* U.S. Pat. No. 4 ~ ~ ~ 4 , 8 8 6  (wil-
lard) to the use of SDS polyacrylamide gel in gel 
electrophoresis wherein the SDS gel binds to proteins 
ity compounds. For a general review of affinity electro- 40 to aid in separation by mass. The SDS is charged and 
phoresis (of macromolecules), see Takeo, Electrophore- the macromolecule creating miform 
S ~ S  5~187-195 (1984). charge per unit area. Thus separation is on the basis of 
Affinity electrophoresis techniques are of enOrmOuS surface area which is related to size. SDS kills cells, 
potential value in a variety of medical biochemical areas which regardless Cannot be subjected to such gel elec- 
(e.g., research, diagnostics). Of particular importance 45 trophoresis. Independent of these blocks9 this method 
are techniques for isolating or separating very large would not aid in separating two mokcular samples of 
molecules or cells such as cancer cells, blood cells, similar mass which have different charges. 
DNA molecules, lymphocytes, proteins, etc. New tech- of neutral Polymers in 
niques are needed since in a great number of cases, the affecting electrophoretic mobility has been examined. It 
cells or particles of interest are not amenable to pres- 50 has been Observed that when freely absorbed, such 
ently known electrophoretic separation techniques. Polymers typically cause an increase, and not a de- 
This is particularly true for cells which are easily dam- crease, in the electrophoretic mobility (see Brooks, J.  
aged by the extreme conditions such as temperature, COhid I n t e ~  sei., 1971 and Seaman, above). Various 
pH, salt concentration or fluid shear inherent in various researchers have employed charged polymers in meth- 
electrophoretic techniques. It is also true that most 55 o d ~  to obtain decreases in the mobility of macromole- 
biological cells have reasonably similar electrophoretic cules but not particles. Examples of these techniques are 
mobilities (approximately 0.9 f0.3 pms- W- km), described in references such as Shimura et al., Electro- 
making them hard to separate electrophoretically. Elec- phoresis 8:135-139 (1987) (charged polylysine added to 
trophoretic particle separation and analysis systems ligand to aid biomolecule separation), and Vestermark, 
need to be specific for various types of particles and 60 German Patent No. 2,040,091 (electrophoretic separa- 
cells. It is extremely important that the range of electro- tion achieved through use of charged polyethylene 
phoretic mobility be entirely controlled such as by the glycol ions). These techniques do not aid in "masking" 
addition of compounds which vary mobility in a spe- the native, Le., effective surface charge of macromole- 
cific manner, and, preferably in a concentration- cules, particles or cells, because the polymers in these 
dependent manner. 65 cases are of opposite charge and will neutralize, not 
The use of affinity agents such as antibodies to en- remove or mask, native charges on the macromolecules. 
hance the specificity of electrophoresis and develop a What has not been previously recognized or accom- 
useful system by which a large number of particles and plished, therefore, is the development of a system by 
As h-kated above, the 
3 
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which hydrophilic. uncharged polymers, such as poly- 
ethylene glycol (PEG). can be used to substantially 
reduce electrophoretic mobility by utilization of their 
polymer segment viscosity properties to alter the hy- 
drodynamic nature of the “surface” of cells. particles 
and macromolecules in a concentration-dependent man- 
ner and/or in a manner based on their specific antigenic 
characteristics. 
It is thus highly desirable to develop a system which 
will be able to employ polyethylene glycol or other 
hydrophilic neutral polymer in an affinity compound 
and which can retard electrophoretic mobility in a con- 
centration-dependent manner so as to allow separation 
of a greater variety of cells, particles, macromolecules, 
or other substances. 
SUMMARY OF THE INVENTION 
According to the present invention, a method of 
reducing electrophoretic mobility of macromolecules, 
particles, cells and other substances in a controlled man- 
ner is provided which comprises interacting the macro- 
molecules, particles or cells with a polymer-linked affin- 
ity compound comprised of a hydrophilic neutral poly- 
mer, such as polyethylene glycol, bound to a compo- 
nent comprising a hydrophobic compound, an im- 
munocompound, such as an antibody or active antibody 
fragment or similar macromolecule with binding speci- 
ficity (e.g., Protein A, Avidin, Protein G, Concanavalin 
A), or a ligand such as a hormone, drug, antigen, en- 
zyme inhibitor or a hapten. The reduction in electro- 
phoretic mobility achievable in the present invention is 
up to about 100% for particular substances, and the 
mobility reduction that is achieved is directly propor- 
tional to the concentration of the interacting affinity 
compound employed. The mobility reduction will also 
be a function of polymer molecular weight. 
The present invention is particularly advantageous in 
that electrophoretic separation is now possible for a 
number of cells or particles whose normal surface 
charge structure would not allow separation under past 
systems. This is achieved with specificity as to particu- 
lar cells or particles that can be separated, and the pres- 
ent invention allows for a controlled, concentration- 
dependent separation for a wide variety of substances. 
BRIEF DESCRIPTION OF THE DRAWING 
FIGURES 
FIG. 1 is a graphic representation of the effects of 
immuno-affinity compounds of the present invention in 
reducing electrophoretic mobility of cells. 
FIG. 2 is a graphic representation of the effects of 
various hydrophobic affinity compounds of the present 
invention in reducing electrophoretic mobility of cells. 
DETAILED DESCRIPTION O F  THE 
PREFERRED EMBODIMENTS 
In the present invention, a hydrophilic neutral poly- 
mer such as polyethylene glycol is used in a two-com- 
ponent system to reduce electrophoretic mobility in a 
wide variety of macromolecules, particles and cells. 
The use of polyethylene glycol has been known in the 
separation of cells, such as described in Karr, Van Al- 
stine et a], .l Chromatography 354: 269-282 (1986), in 
which it is employed in a phase partitioning system. 
However, phase partitioning, a liquid-liquid extraction 
technique which is relatively three-dimensional and 
energy independent, is quite unrelated to electrophore- 
sis procedures, which are energy dependent and in- 
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4 
volve Iinear separation of materials based on differences 
in apparent surface charge. It has also been disclosed in 
a previous U.S. Pat. No. 4,690,749 (Van Alstine et al), to 
employ PEG in controlling electroosmosis. However,, 
in that patent, the PEG is permanently (Le., covalently) 
linked to the surface of nonliving particles so as to pro- 
duce test particles, e.g., glass beads, of defined mobility. 
In the present invention, the PEG-linked affinity com- 
pounds do not permanently bind to the particle or cell 
separated, and the technique disclosed herein can be 
used specifically for separating desired or target cells, 
after which the affinity ligand is released from and/or 
metabolized by those cells. 
In the embodiments of the present invention, the 
polymer-linked affinity compound employed to reduce 
electrophoretic mobility in a controlled manner will be 
comprised primarily of a hydrophilic neutral polymer 
and a second component consisting of a hydrophobic 
compound, an immuno-compound, including antibod- 
ies, active antibody fragments or similar macromole- 
cules with binding specificity (e.g., Protein A, Avidin, 
Protein G, Concanavalin A), or a ligand. For all of the 
embodiments, it is preferred that the hydrophilic neutral 
polymer neutral polymer employed comprise polyeth- 
ylene glycol (PEG). However, other hydrophilic neu- 
tral polymers which can be covalently coupled to the 
second component of the polymer-linked affinity com- 
pound may be employed and may be advantageous 
under certain specific applications. Such advantages 
may include solubility, nonspecific interaction with 
substances of interest, chemical modification, FDA 
approval, secondary antigenicity, etc. Other neutral 
hydrophilic polymers suitable for use in the invention 
include polyvinyl alcohol, polyvinyl pyrrolidone, poly- 
propylene glycol, polyethylene glycol-polypropylene 
glycol co-polymers, and polypropylene glycol- 
polyethylene glycol co-block polymers. 
As discussed previously, it had been observed that 
free adsorption of neutral polymers typically increased 
the electrophoretic mobility of particles and cells. This 
is most likely due to the fact that the particles or cells 
non-specifically adsorb the polymers at multiple poly- 
mer contact points on their surface (see Brooks, above 
and Seaman, above). In the present invention, the hy- 
drophilic neutral polymer-containing compounds ad- 
sorb at the “surface” of the macromolecule, cell or 
particle via demonstrably specific interactions. As a 
result, these adsorbate neutral affinity compounds alter 
particle or molecular electrohydrodynamic interaction 
with the suspending medium (increase local viscosity) 
at the particles or macromolecule’s “surface”, lowering 
ceWparticle mobility. In the case of macromolecules, 
the affinity compounds of the present invention simi- 
larly contact the macromolecule at its outer periphery 
and alter its hydration, and the effect in reducing elec- 
trophoretic mobility is analogous to the effect of the 
compounds on the outer layers of cell or particle sur- 
faces. 
In one of the preferred embodiments of the invention, 
an immunocompound or fragment thereof, is employed 
as the second component of the polymer-linked affinity 
compound. By immunocompound is meant antibodies 
or fragments thereof, or similar compounds (such as 
Concanavalin A, Protein G, Protein A, Avidin) which 
can bind to specific “antigens”. Particularly useful in 
the present invention are immunoglobulins (e.g., IgG) 
and their active fragments (e.g., F(ab) or Fc) derived 
therefrom. However, any antibody of human or animal 
5,108,568 
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derivation may be successfully employed in the inven- definition will be apparent to one skilled in this field. 
tion. It has been shown by a group of authors including One preferred hydrophobic compound for use in the 
Karr, Harris, Van Alstine, et al., that PEG derivatized present invention comprises a fatty acid or alcohol alkyl 
Protein A (which binds to antibody molecules) can be derivative or acyl group with a hexadecane, octadec- 
used to effect immunoaffinity partition. This technique 5 ane, etc. tail including palmitic acid, stearic acid, oleic 
may also work for immunoaffinity electrophoresis using acid, etc. However, other hydrophobic compounds 
PEG-Protein A or PEG-Protein G and unmodified which can be covalently linked to the hydrophilic neu- 
antibodies or PEG-Avidin and Biotin-conjugated anti- tral polymer, such as 1-amino-octadecane may also be 
bodies, etc. Affinity compounds containing an im- employed. Still other hydrophobic compounds contem- 
munocompound as the second component are particu- 10 plated as suitable for use in the present invention would 
larly advantageous in that they can be made very spe- include steroids, glycolipids, phospholipids, and other 
cific to the particular cell, particle, or macromolecule similar compounds. The specific hydrophobic com- 
desired to be separated, and can then be used according pound used in any particular application will of course 
to the method of the invention to successfully reduce be dependent on the desired cell, particle or macromol- 
mobility in a large number of substances having a sur- 15 ecule to be separated. 
face or outer periphery charge structure which nor- The hydrophilic neutral polymer-hydrophobic affin- 
mally would not allow them to be separated by electro- ity compounds employed in the present invention can 
phoretic means. Immuno-affinity compounds can thus be prepared by any suitable process conventionally 
be modified in accordance with the method of the in- known and used in the art. However, it is preferred that 
vention and rendered effective in reducing electropho- 20 the hydrophobic compounds be linked to the hydro- 
retic mobility of specific particles (e.g., cells such as philic neutral polymer by means of a covalent linkage, 
subpopulations of lymphocytes) or any other molecules and it will be obvious to one skilled in the art that this 
to which the antibodies or their active fragments are can be carried out in a number of ways. It is preferred 
directed. that a hydrophobic compound, such as a fatty acid or 
An additional feature of this aspect of the invention is 25 alcohol alkyl derivative, be combined with a PEG hy- 
the observation that the antibodyheutral polymer com- drophilic neutral polymer by suitable ether, amide, or 
pounds greatly reduce the tendency to aggregate cells ester linkage. In general, however, the hydrophobic 
or particles, which would hinder specific cell separa- compounds are most preferably linked to the hydro- 
tion, while at the same time providing concentration- philic neutral polymer by means of an ester linkage 
dependent reduction in cell or particle electrophoretic 30 (such as those used in Example 2), but linkage through 
mobility. The immuno-affinity compounds of the pres- an ether, amine or other functional group is possible, 
ent invention are a great improvement over previous and in certain cases may be beneficial. For example, 
compounds as reported above which only achieved up ether linkages may confer longer shelf storage life. See, 
to about 40% reduction in electrophoretic mobility. In e.g., Harris, Van Alstine et al., ACS Indus. Eng. Prod. 
the present invention, reduction in effective mobility of 35 R+D 23536-88 (1989). 
up to 100% can be achieved, in a manner dependent on The hydrophobic affinity compounds of the present 
the concentration (Le., amount of bound antibody). invention show some specifity as to the cells and parti- 
The preparation of hydrophilic neutral polymer- cles for which mobility is to be reduced, and these com- 
linked affinity compounds such as a PEG-antibody will pounds have been shown by nonelectrophoretic meth- 
preferably carried out by any of the many conventional 40 ods to have differential interactions with specific cells 
processes generally known in the art.' The covalent such as normal and cancer cells, or different species of 
coupling of polyethylene glycol to an IgG antibody has red blood cells. A particular advantage of the hydro- 
been disclosed in Karr, Van Alstine et al., J.  Chromatog- phobic affinity compounds as used in the method of the 
raphy 345269-282 (1986), incorporated herein by refer- invention is that the binding with the cells treated is 
ence. In this preferred preparation process, the polym- 45 readily reversible. This feature is highly advantageous 
er-linked affinity immunocompound of the present in- where it is desired to separate cells, then remove the 
vention is prepared by mixing rabbit IgG directed affinity compound so that the separated cells can be 
against stroma from human red blood cells (RBC's), examined in native state. The compounds are not harm- 
Fab fragments from the rabbit IgG, and an enriched ful to the electrophoretic apparatus used, and are typi- 
IgG faction from sheep with cyanunic chloride- 50 cally employed and in such low concentrations that 
activated PEG 5000 or PEG 1900 monomethylether in they can be easily and cheaply added to the buffer solu- 
a borate buffer. An approximately equimolar amount of tions normally used in existing electrophoretic tech- 
activated PEG 5000 relative to IgG lysine amino niques. 
grounds resulted in about 50% modification of the ly- In still another aspect of the present invention, the 
sine amino groups. Unattached PEG was removed from 55 second component of the polymer-linked affinity com- 
the resulting mixture by diafiltration with 10 volumes of pound comprises a ligand. Ligands are well known as a 
0.05 M borate buffer and 0.025 M sodium acid. It will be chemical class, and their definition will be well known 
well understood to those skilled in the art that many to one skilled in the art. Ligands useful in the present 
alternative methods of preparing the polymer-linked invention include a wide variety of small macromolecu- 
affinity compounds of the invention are known and can 60 lar substrates, such as hormones or antigens, or low 
be employed, and particular methodology will depend molecular weight substances such as enzyme inhibitors 
upon the precise nature of the hydrophilic neutral poly- and haptens. Still other ligands contemplated as suitable 
mer and the second component which are employed in for use in the invention include neurotransmitters or 
the affinity compound. mimetic drugs known to target specific cells, tissues or 
In another embodiment of the present invention, the 65 proteins. Examples of such substances include ouabain, 
second component in the polymer-linked affinity com- nicotine, acetylcholine, etc. 
pound comprises a hydrophobic compound. Hydropho- As with the previously described embodiments, the 
bic compounds are well known in the art and their affinity compounds of the present invention which in- 
5,108,568 
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clude ligands are prepared in any of a number of con- 
ventional ways presently known in the art. One pre- 
ferred method would comprise reacting an activated 
hydrophilic neutral polymer such as activated PEG 
5000 or PEG 2oooO with a ligand such as by the cyanu- 
ric chloride method described above. Such chemistry, 
directed at goals not overlapping the present patent 
application. are described in a variety of publications 
such as Karr, Van Alstine et al, J.  Chromatography 
345:269-282 (1986). However, it will be clear to one 
skilled in the art that a number of alternative prepara- 
tion procedures can be employed, and the particular 
procedure chosen will depend on the particular hydro- 
philic neutral polymer and ligand used, and the target 
cell, macromolecule, or particle separated. 
The present invention differs from the previous work 
of Muller et al, Nucleic Acid Research 9:95-115 (1981), 
in which dyes were covalently bound to a polyethylene 
glycol to specifically increase the frictional “surface” 
coefficient of DNA molecules gel electrophoresis, in 
that the Muller et a1 article did not disclose use of the 
dyes in binding cells or other particles. The ligand- 
affinity compounds of the present invention can be 
employed to reduce the non-gel based electrophoretic 
mobility of cells and particles in addition to macromole- 
cules. Additionally, the ligand-affinity compounds of 
the present invention will be of varying reversibility, 
depending upon the particular ligand chosen, and re- 
duce the mobility of cells and particles in a concentra- 
tion-dependent manner. The ligand can be covalently or 
non-covalently bound to the hydrophilic neutral poly- 
mer as desired for a particular separation procedure. 
In accordance with the present invention, electro- 
8 
polymer-linked affinity compounds of the invention can 
thus be used in a variety of applications when it is de- 
sired to achieve enhanced reduction of electrophoretic 
mobility in a controlled, concentration-dependent man- 
The present invention is advantageous in that the 
affinity compounds prepared as described above can be 
used in a wide variety of conventional electrophoretic 
apparatuses and methods in order to achieve separation 
10 for a great range of substances including cells, macro- 
molecules and particles. By cells, it is generally meant 
the great diversity of biological or nonbiological cells, 
e.g:, cancer cells, red blood cells, white blood cells, 
artificial cells, etc. which are often difficult to separate, 
15 but must be isolated for the great variety of research 
and diagnostic procedures performed using such mate- 
rials. By macromolecules, it is generally contemplated 
that this will include many macromolecules known 
which are commonly isolated in research, most com- 
20 monly those having molecular weights of generally 
anywhere from about 200 to lO,OOO,OOO daltons. In- 
cluded in this definition would be biological macromol- 
ecules such as DNA, proteins, protein active units, 
RNA, etc. By particles is meant any substance ,which 
25 does not fit any of the other classes above, but which 
has a definite mass and shape, and which can be isolated 
and separated by electrophoretic means. This will in- 
clude bioparticles such as cell organelles, viruses, bac- 
teria, yeasts, nuclei, nuclear fragments, membrane frag- 
30 ments, etc., and non-biological materials such as lipo- 
somes, polymer beads, micelles, and standard particles. 
Although particles of almost any size will be suitable for 
use in the present invention, the invention generally 
5 ner. 
phoretic separation can be accomplished in a variety of contemplates separating particles with sizes of from 
different manners. Depending on the affinity compo- 35 about 0.001 to 200 microns in diameter. It will be clear 
nent utilized, separation can be achieved on the basis of to one skilled in the art that the choice of which affinity 
specific/irreversible (e.g., PEG-derivatized antibody), compound to use will greatly depend on the substance 
specific/reversible (e.g., PEG-derivatized lectin), semi- to be separated, and whether other factors such as speci- 
specific, reversible (e.g., PEG-hydrophobic affinity ficity or reversibility (as discussed above) are crucial. 
ligand such as unsaturated PEG-fatty acid ester), rela- 40 In carrying out the method of the present invention, 
tively nonspecific reversible (e.g., saturated PEG-fatty the polymer-linked affinity compounds described above 
acid ester or PEG-ionic interaction group (trimethyl- are interacted with the target particle, cell, macromole- 
amine or sulphate)) or relatively nonspecific-irreversi- cule, bioparticle or other substance in an electropho- 
ble (e.g., PEG-cyanuric chloride reacting with amino retic system (such as gel electrophesis) in any of the 
possessing particles or molecules) interactions. 45 many known conventional procedures commonly car- 
In general, the affinity compounds appear to operate ried out in such a system. Generally, this will include a 
in reducing mobility of the macromolecules, cells, or first step of introducing the desired polymer-linked 
particles treated by masking the “effective or apparent” affinity compound to a sample containing the particles 
surface charge. The neutral polymers apparently in- or macromolecules to be separated which has been 
crease fluid viscous resistance to “surface” flow when SO prepared for the appropriate electrophoresis apparatus 
anchored via the second component of the affinity com- chosen, followed by carrying out the particular electro- 
pound to the particular cell, particle, or macromolecule phoretic technique chosen to best separate the target 
separated. A general background as to the theory of component. For example, in one preferred operation of 
electrophoresis and the effects of increasing local sur- the present invention, a polymer-linked affinity com- 
face resistance to fluid flow can be found in Levine et al, 55 pound comprised of an antibody linked to polyethylene 
Biophys. J. 42:127-135 (1983). In the present invention, glycol (PEG) was used to specifically decrease the 
the more neutral polymers which can be attached to the mobility of a sample of biological cells comprised of 
unit to be separated, the greater the effect in reducing human erythrocytes. The PEG-Ab was added to the 
mobility. Thus the reduction in electrophoretic mobility cells in a phosphate buffered saline solution, and the 
may be obtained in a manner directly proportional to 60 separation was carried out using a Rank Bros. cylindri- 
the amount of affinity compound employed in the elec- cal chamber cytropherometer set at 40 Volts DC. In 
trophoretic assay. The ability of the affinity compounds experimental procedures conducted using this appara- 
of the present invention to achieve concentration- tus, it was observed that use of the affinity compounds 
dependent reduction in electrophoretic mobility has of the method of the present invention decreased cell 
been confirmed in experimental tests. Their ability to 65 mobility in a concentration dependent manner. 
specifically interact with a variety of biological and The inventive method is not limited to any particular 
nonbiological substances (particularly cells) in a con- mode of operation, and it will be clear to one skilled in 
centration dependent manner is documented. The the art that the method of the present invention can be 
5,108,568 
9 10 
EXAMPLE 11 
Preparation of Other PEG-Linked Affinity Compounds 
The preparation of other PEG-linked compounds has 
J.  polymer 
sei. 22:341-352 (1984), incorporated herein by refer- 
ence. This reference describes five general routes to 
synthesize PEG derivatives, and included preparation 
of the following PEG-linked compounds: 
PEG- Aldeh yde 
This compound was prepared by three different 
routes. The first route, oxidation with pyridinium chlo- 
,5 rochromate, is described in the Hams, Van Alstine et al. 
J.  Polymer Sci. article, and the second and third routes 
proceeded as follows: * 
Preparation of Polymer-Linked Affinity Compounds (i) From the diethyl acetal of a-bromoacetal- 
and the 
BrCHzCH(OC2H5)2 (1.0 mL) was then added to drop- 
wise and stirred continuously for 12 h. The reaction 
mixture was added to 200 mL dry ethyl ether and the 
and stirred for 30 min. Absolute ethanol (50 mL) was 
stroma from human RBCs (native antibody) which was ethanol if necessary). The crude, wet product was 
U.S.A. (lot 22196). Fab fragments derived from this warm ethanol by addition to 100-150 mL dry ethyl 
enriched IgG fraction frqm sheep, also directed against end groups was determined by Schiff test to be 65%. 
versity of British Columbia, Vancouver, Canada. This 35 3400 (5 g, 1.7 mmol) was added to o.4 acetic anhy- 
fraction, which had been derived from whole serum by dride in 15 m~ dimethylsulfoxide and stirred for 30 h at 
ammonium sulfate precipitation, was then further puri- temperature. At this point the reaction mixture 
tied by ion exchange chromatography using a DEAE- was added dropwise to 100 mL dry ethyl ether, and 
silica gel cohmn. Both IgG samples reprecipitated two or three times from methylene chlo- 
human RBCS at Concentrations less than 0.2 pg/ml but ride with ethyl ether. Yield was 4.5 g. The product 
did not agglutinate sheep RBCs. retained a faint smell of dimethylsulfoxide. HPLC anal- 
In a typical Preparation of the PEG-antibodY corn- ysis showed no chain cleavage, and reduction with 
Fund,  12 mg of Protein in 0.5 ml 0-05 M NazB4O7, PH tritiated NaBH4 indicated 80% aldehyde end groups. 
9-29 was added to 1-5 ml0.1 M borate buffer. A 45 Reaction for longer periods, with excess anhydride, or 
of 1 ml of cyanuric Chhide-activated PEG 5000 Or at higher temperatures gave lower percentages of alde- 
PEG 1900 monomethyl ether in the borate buffer was hyde end groups. 
then added at 4" C., and the mixture was stirred for Ofthe three routes to the aldehyde, the DMSO-Ac20 
hour. Unattached PEG was removed by diafiltration approach Seems to be the best in terms of ease of reac- 
(50-ml Amicon cell, PM-30 membrane, 30,000 mOleCu- tion and product purity. 
lar weight cutoff) with 10 volumes of 0.05 M borate 
buffer and 0.025 M sodium azide to a final volume of 2 PEG-Amine 
ml. Typically 27 mg of activated PEG 5000, approxi- Potassium hydroxide (0.02 g, 0.4 mmol) was added to 
mately equimolar relative to IgG lysine amino groups ammonium chloride (0.36 g, 6.7 mmol) in 5 mL metha- 
(90 per molecule) resulted in about 50% modification of 55 nol. After the KOH pellets had dissolved, PEG-CHO 
the lysine amino groups; only 70 of the 90 lysine groups (for 3000 g/mol, 2.0 g, 0.67 mmol) was added and the 
were sensitive to our method of analysis (below). About solution stirred for 15 min. A solution of NaCHBH3 
half this amount of activated PEG (14 mg) gave 30% (0.42 g, 6.7 mmol) in 5 mL methanol was then added 
modification. dropwise over 30 min., followed by addition of a second 
Analysis was performed by the Biuret and Habeeb 60 pgrtion of KOH (0.1 g, 1.8 mmol). The solution was 
methods (see Karr, Van Alstine, J.  Chrom. stirred for 24 h, and the product then precipitated by 
345:269-282). For the latter method (based on reaction addition to ether. Recovery of the product was made 
of trinitrobenzenesulfonic acid with free lysine groups), difficult by its gummy nature which necessitated cen- 
we found it necessary to remove unattached PEG and trifugation rather than filtration. HPLC revealed no 
to keep protein concentrations at approximately 0.6 65 chain cleavage. A nitrous acid test was positive, and a 
mg/ml in order to obtain accurate and reproducible Schiff test was negative. Chemical analysis is as follows: 
results. The 0.1 M borate buffer was used rather than Calcd C, 54.4; H, 9.09; N, 0.45. Found: C, 54.8; H, 
4% NaHCO3 called for in the original procedure. 9.94; N, 0.88. 
suitably carried out using a variety of conventional 
electrophoretic techniques and apparatuses. Included in 
such techniques would be systems employing equip- 
ment for carrying out capillary electrophoresis, gel 
electrophoresis, cylinder electrophoresis, continuous 5 been described in ~ ~ ~ ~ i ~ ,  van Alstine et 
flow electrophoresis, slab gel electrophoresis, etc. The 
present invention will thus be applicable to a Variety Of 
conventional electrophoretic Systems, and Will be ex- 
tremely advantageous in separating many substances 
which previously could not be separated in such sys- lo 
tems. 
The following examples are presented as illustrative 
only and are not intended to limit the scope of the in- 
vention in any way: 
EXAMPLE I 
The preparation of a pEG-antibody compound has 
Chromarography 345:269-282 (1986). In this example, a 
dehyde-potassium tert-butoxide (1.0 g) was added to 
mixture was stirred at room temperature for 30 min. 
been previous described in Karr, Van Alstine et a]., J.  20 5g PEG-3400 in 30 mL dry benzene Or 
polyethylene glycol (PEG) was covalently coupled to 
IgG antibodies in the manner described below. Unless 
or better quality, obtained from commercial sources. 25 
specified otherwise, all reagents used were ACS grade, 
Distilled, filtered, 12 Mfi/cm water was used through- 
Out. The antibody used was Rabbit IgG directed against 
resulting p ~ ~ - ~ ~ ~ ~ ~ l  filtered, 
added and the solution in a refrigerator at 0" c. 
for 2-3 h until the pEG-aldehyde had crystallized (add 
in 20 m~ 2 M HCI 
obtained from Cooper 3o purified further by twice precipitating from 10-15 mL 
Same lot were prepared by controlled papain digestion 
by Jackson Immunoresearch~ Pa., U.S.A. An 
human RBCS, was provided by Dr. D. E. Brooks, Uni- 
ether. Yield: 4.5-5.0 PEG-CHO, HPLC analysis re- 
vealed no chain cleavage. The percentage of aldehyde 
(ii) B~ D M S O - ~ ~ ~ ~ ~ ~  anhydride oxidation-pEG- 
11 
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We have found it difficult in general to obtain good 
elemental analyses on PEG derivatives because, we 
believe, of the tendency of these compounds to absorb 
protic solvents and salts. 
PEG-Octadecyl Amine 
sler's reagent for PEG. Approximately 100 mL water 
eluent were required for each gram of PEG to remove 
underivatized PEG from the column. After PEG could 
no longer be detected in the water eluent., 500 mL 5:1 
5 methanol: water were amlied to elute the ester. The 
The tosylate of PEG-3680 (monomethyl ether; 0.5 g, 
0.14 mmol) and octadecyl amine (p.180 g, 0.67 mmol) 
.were dissolved in benzene (10 mL) with a suspension of 
0.2 g anhydrous sodium carbonate. This mixture was 
stirred at reflux for 60 h, and then the product precipi- 
tated by dropwise addition to 100 mL anhydrous ethyl 
ether. The reaction was monitored by inclusion of a 
small amount of "Clabeled octadecyl amine (New 
England Nuclear). Yield was 0.42, g, 90% substitution. 
PEG-Monopalmitate 
PEG-6000 (Union Carbide; 20 g) was dissolved in 100 
mL toluene, and 20 mL toluene were removed by distil- 
compound was then isolated by rotary evaporation and 
freeze drying. Over 95% of the material applied to the 
column was recovered. The original mixture contained 
approximately one esterified PEG molecule in 60, while 
0 the final product contained 46 esterified molecules in 
60. We have used the above procedure to prepare PEG- 
esters of the following fatty acids: 18:l; 12:O; 14:0; 16.0; 
16:l; 18:O; 18:2; 18:3; and 20:4. 
The PEG concentration of chromatography fractions 
was monitored by use of Nessler's reagent (Fisher). 
Sample (25 pL) was added to 5 mL Nessler's solution, 
mixed well, and allowed to settle for 2 min. The absor- 
bance at 600 nm was read and compared with a standard 
20 
25 
30 
35 
curve. Because of nonlinearity of the Beer-Lambert 
plot, it was necessary to dilute samples to keep absor- 
bance below 0.6 units. 
The percentage of esterified PEG end groups was 
determined with the hydroxamic acid assay. The hy- 
droxylamine reagent was prepared shortly before use 
by mixing equal volumes of 2 M HCI in propano1:water 
(4 vol/l vol) was added to the tubes which were re- 
capped and mixed. Then 100 pL of this sample were 
mixed with 400 pL alkaline hydroxylamine reagent. 
After 20 to 25 min., 400 pL 2 MHCl in propano1:wa- 
ter (4 vol/l vol) was added to the tubes which were 
recapped and mixed. Then 100 p1 propanol, 100 p L  
methanol/water (5 vol/vol), and 200 p L  0.37 M FeCI3 
in 0.1 M HCI were added to each tube and the contents 
mixed. After 10 min the absorbance at 515 nm was 
measured and the result compared with a standard 
curve prepared from methyl esters of stearic, linolenic, 
or lauric acids (all standard curves were identical). 
lation to remove water. Triethylamine (0.4 g; distilled 
over calcium hydride) was added to the PEG-toluene 
solution. 
Palmitic acid (0.1 g; specific activity 5.9 mCi/mmol; 
Amersham) was dissolved in 2 ml 1.0 M NaOH in meth- 
anol to prepare the salt, and the solvent then removed 
by lyophilization. The lyophyiate was dissolved in 10 
mL anhydrous ethyl ether, to which was added drop- 
wise 2 mL oxalyl chloride. The solvent was removed by 
rotary evaporation, and the residue resuspended in 10 
mL toluene. 
The PEG and acid chloride solutions were mixed and 
heated to reflux for 10 min. Cooling to 4" C. resulted in 
precipitation of the product. Yield was 19 g. 
The product was purified in the three stages. In the 
first stage 12 g product was repeatedly (five times) 
dissolved in 200 mL acetone (slight warming aids solu- 
tion) and precipitated by addition to 300 mL anhydrous 
ethyl ether at 0" C. TLC on silica gel (solvent D) 
cleanly separated PEG and PEG-ester (Rf=0.08) from PEG-Octadecyl Ether 
the fatty acid (Rf =0.85), and revealed that the fatty 40 
acid contaminant had been reduced to 0.3% (w/w). PEG-6000 (10 g; 0.0017 mol) was dissolved in 40 mL 
In the second stage the remaining fatty acid impuri- dry benzene and added dropwise to a suspension of 
ties were removed by chromatography on Sephadex Potassium t-butoxide (10% excess; 0.4 g; 0.0037 mol) in 
LH-20 gel (Pharmacia) with 5:l methanol: water eluent. 20 mL dry benzene under a nitrogen atmosphere. The 
This step reduced free fatty acid content to less than 45 mixture was allowed to stir at room temperature for 1 
0.1 % (w/w) as shown by TLC. In a typical run, 10.5 g hour. OctadecYl bromide (two time excess; 2.2 g; 0.0067 
PEG/PEG-ester mixture were dissolved in 180 mL 5:1 mol) was dissolved in 15 mL dry benzene and added 
methano1:water and loaded on the column at 120 mL/h dropwise to the mixture, which was then stirred at 
and elution continued until 2.0 L solvent had passed rOOm temperature for 72 h. After filtration to remove 
through the column. The gel column was prepared 50 insoluble salts, the benzene was removed by rotoevapo- 
from 350 g LH-20 and had final dimensions of 66 x 20 ration. The product was redissolved in methylene chlo- 
cm2. Altering flow rate had little effect on separation ride and eluted down a short silica gel column (1 in. x 5 
efficiency, but increasing sample concentration (viscos- in.) with methylene chloride. This removed dissolved 
ity) dramatically reduced separation. Fractions were salts and some of the unreacted PEG. The eluent was 
analyzed with Nessler's reagent, scintillation counting, 55 concentrated by rotoevaporation and the PEG-ether 
and hydroxamic acid ester assay. Recovery was greater precipitated by dropwise addition to diethyl ether. 
than 95% in all cases. Product isolated by precipitation was gummy and diffi- 
In the third stage the monoester (and any diester) cult to filter. The product was further purified by chro- 
were separated from unsubstituted PEG by chromatog- matography on Sephadex LH-20 gel with 5:l me- 
raphy on octylsepharose CL4B (Pharmacia). In a typi- 60 thano1:water eluent (1 g dissolved in 30 mL eluent on a 
cal run, 7 g PEG and PEG-ester in 5:l methanol: water 1 in. X 12 in. column with a flow rate of 0.5 mL/min). 
(from the LH-20 chromatography) were placed in a The eluent was concentrated by rotoevaporation and 
rotary evaporator and the methanol removed. The sam- dried several hours in vacuo. Product thus isolated was 
ple was then made up to 170 mL in water and applied to 75-90% substituted with 0.2% (w/w) alkyl bromide 
the column at a flow rate of 40 mL/h followed by water 65 contaminant remaining. Yield was 60%. 
elution at 60 mL/h. The column distensions were Alkyl bromide remaining was determined by GLC 
30x53  cm2 (Pharmacia K26/40 column) with a 200 (30% SE-30). Substitution was determined by PNMR 
mL bed volume. Fractions were analyzed with Nes- by determining the alkyl-H/ether-H ration, by HPLC 
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(C18, 65:35 acetonitri1e:methanoI). and also by C-H 
elemental analysis. 
EXAMPLE I11 
Interactions of Affinity Compounds In Electrophoretic 
Tests 
Electrophoretic mobility profiles of standard model 
cells (human erythrocytes) were obtained by interacting 
a PEG-antibody prepared in the manner of Example I 
with the cells in phosphate buffered saline in a Rank 
Bros. cylindrical chamber cytopherometer set at 40 V 
DC. Standard cell mobility is roughly 1.1 micrometer 
per second per volt per cm (Le., velocity per field 
strength) expressed as pm s-1 V-1 cm. Five separate 
* experiments with polyethylene glycol-immunoglobulin 
used to treat the cells were run, and the results are 
observed in the graph of FIG. 1. Each different immu- 
noglobulin is represented by a different symbol. The 
standard error associated with each measurement 
(point) was +lo%, or less, of the mean. The results 
indicated that cell mobility was decreased for all PEG- 
immunoglobulin treated cells in a concentration depen- 
dent manner. The range of reduction ranged from 
roughly 1 pg to 1 mg, and at the higher concentration 
levels of PEG-IgG, cell mobility effectively ap- 
proached zero or a 100% reduction in mobility. It was 
also noted in these tests that cell aggregation normally 
associated with treatment by immunoglobulins alone 
was not observed with the PEG-immunoglobulin affin- 
ity compounds of the present invention. 
EXAMPLE IV 
The effect of a PEG-fatty acid ester affinity com- 
pound on cell mobility was tested in the same manner as 
described in Example 111. The results of these tests can 
be observed in FIG. 2. Tests were made on PEG alone 
(as a control), and on PEG-fatty acid ester compounds 
varying in fatty acyl tail length and saturation. The 
PEG employed in most of these trials had a molecular 
weight of roughly 8000, and in one of the tests, a PEG 
of molecular weight of about 1000 was studied. The 
tests involved 3-5 trials for each of the affinity com- 
pounds as indicated in FIG. 2. Typical standard devia- 
tion for each point was &lo%, or less, of the mean. The 
results again indicated that the PEG-fatty acid ester 
affinity compounds were successful in producing a con- 
centration-dependent reduction in electrophoretic mo- 
bility of the treated cells. It was also determined that the 
reduction in mobility was dependent upon the PEG 
head group molecular weight and the fatty acyl tail 
length and saturation. The particularly effective affinity 
compounds were those indicated at C-F in FIG. 2, 
wherein molecular weight of the PEG was around 
8000, and the acyl tails of the compound had substantial 
tail length (hydrophobicity). The trials with lower mo- 
lecular weight PEG and shorter tail length compounds 
both affected the mobility of the cells, but not as greatly 
as the effect observed with the compounds C-F. 
The hydrophobic affinity compounds of the inven- 
tion, although not as specific as the immuno-affinity 
compounds such as described in Example 4, are advan- 
tageous in that they can be produced at low cost, and 
are easily reversible with regard to the cells treated. 
Most cells have similar native electrophoretic mobilities 
due to the nature of the surface charges involved. The 
affinity compounds of the present invention will there- 
fore allow for the controlled electrophoretic separation 
of cells and other particles in a manner heretofore una- 
14 
chievable, using equipment already owned by many 
laboratories. 
EXAMPLE V 
It is contemplated that a PEG-ligand affinity com- 
pound interaction will be carried out using the drug 
streptozotocin, which is specific for insulin-producing 
pancreatic Beta islet cells. Coupling PEG to strep- 
tozotocin may allow Beta cells to be separated electro- 
10 phoretically from a mixture of cells from minced pan- 
creatic islet tissue in that the Beta cells would be held 
back while the other cells (Delta, Alpha, fibroblasts, 
etc.) migrated at their normal mobility. In this interac- 
tion, coupling PEG to the streptozotocin will prevent it 
l5 crossing the cell bilayer by diffusion (which can have 
harmful effects on cell viability). Separations based on 
other drugshormones coupled to PEG should also be 
readily possible, as one skilled in the art would be led to 
believe by the data embodied in the graphs of FIGS. 1 
5 
2o and 2. 
What is claimed is: 
1. A method of reducing electrophoretic mobility of 
macromolecules, particles cells or other substances in a 
controlled manner comprising interacting the sub- 
25 stances with a polymer-linked affinity compound com- 
prising a hydrophilic neutral polymer bound to a hydro- 
phobic compound comprising a compound selected 
from the group consisting of a fatty acid or alcohol 
derivative, steroids, glycolipids, phospholipids and sim- 
ilar compounds so that a reduction of electrophoretic 
mobility of the treated substance is obtained that is 
directly proportional to the concentration of the polym- 
er-linked affinity compound used in the interaction. 
2. A method according to claim 1 wherein the hydro- 
philic neutral polymer comprises polyethylene glycol. 
3. A method according to claim 1 wherein the hydro- 
philic neutral polymer is selected from the group con- 
sisting of polyvinyl alcohol, polyvinyl pyrollidone, 
40 polypropylene glycol, polyethylene glycol-polypropy- 
lene glycol co-polymers, and polypropylene glycol- 
polyethylene glycol co-block polymers. 
4. A method according to claim 1 wherein the hydro- 
phobic compound is bound to the hydrophilic neutral 
5. A method according to claim 1 wherein the hydro- 
phobic compound is bound to the hydrophilic neutral 
polymer by means of an ether linkage. 
6. A method according to claim 1 wherein the hydro- 
50 phobic compound is bound to the hydrophilic neutral 
polymer by means of an amine linkage. 
7. A method according to claim 1 wherein the hydro- 
phobic compound is covalently bound to the hydro- 
philic neutral polymer. 
8. A method of reducing electrophoretic mobility of 
macromolecules, particles, cells or other substances in a 
controlled manner comprising interacting the sub- 
stances with a polymer-linked affinity compound com- 
prised of a hydrophilic neutral polymer bound to a 
60 compound capable of binding to a specific antigen, said 
compound comprising a compound selected from the 
group consisting of an antibody, an immunoglobulin, an 
active antibody fragment, an active immunoglobulin 
fragment, Protein A, Protein G, avidin, concanavalin 
65 A, wheat germ lectin and other lectins capable of bind- 
ing to a specific antigen, so that reduction of electro- 
phoretic mobility of the treated substances is obtained 
that is directly proportional to the concentration of the 
30 . 
35 
45 polymer by means of an ester linkage. 
55 
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polymer-linked affinity compound used in the interac- 
tion. 
9. A method of reducing electrophoretic mobility of 
macromolecules, particles, cells or other substances in a 
controlled manner comprising interacting the sub- 5 
with a po]ymer-linked affinity compound 
prised of a hydrophilic neutral polymer non-cova]ently 
bound to a ligand so that a reduction of electrophoretic 
mobility of the treated substances is obtained that is 
directly proportional to the concentration of the polym- 
er-linked affinity compound used in the interaction. 
A method according to claim wherein the ligand 
is selected from the group consisting of hormones, 
drugs, antigens, enzyme inhibitors haptens, neurotrans- 
mitters, ouabain, nicotine, acetylcholine, and other mi- 
metic drugs. 
* * * * *  
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